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Abstract: 
Epigenetics studies factors related to the organism and environment that modulate inheritance from generation to generation. 
Molecular epigenetics examines non-coding DNA (ncdDNA) vs. coding DNA (cdDNA), and pertains to every domain of 
physiology, including immune and brain function. Molecular cartography, including genomics, proteomics, and interactomics, 
seeks to recognize and to identify the multi-faceted and intricate array of interacting genes and gene products that characterize the 
function and specialization of each individual cell in the context of cell-cell interaction, tissue, and organ function. Molecular 
cartography, epigenetics, and chromatin assembly, repair and remodeling (CARR), which, together with the RNA interfering 
signaling complex (RISC), is responsible for much of the control and regulation of gene expression, intersect.   
 
We describe current and ongoing studies aimed to apply these overlapping areas of research, CARR and RISC, to a novel 
understanding of the immuno-neuropathology of HIV-1 infection, as an example. Taken together, the arguments presented here 
lead to a novel working hypothesis of molecular immune epigenetics as it pertains to HIV/AIDS, and the immunopathology of 
HIV-1-infected CD4+ cells. Specifically, we discuss these views in the context of the structure-function relationship of 
chromatin, the cdDNA/ncdDNA ratio, and possible nucleotide divergence in the untranslated regions (UTRs) of mature mRNA 
intronic and intergenic DNA sequences, and putative catastrophic consequences for immune surveillance and the preservation of 
health in HIV/AIDS. Here, we discuss the immunopathology of HIV Infection, with emphasis on CARR in cellular, humoral and 
molecular immune epigenetics.  
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Background: 
Close to 98-99% of the eukaryotic genome consists of DNA 
that is not translated (i.e., non-coding). A proportion of non-
coding DNA may have regulatory functions, and seem to 
control developmental and physiological pathways, and 
responses to pathological processes [1]. But the function of 
the remaining non-coding portions is unclear. Peptides, 
hormones, and other biological molecules (e.g., drugs of 
abuse) probably bind to specific elements of chromatin, 
hence altering its structure and its function. This may modify 
the coding DNA/non-coding DNA ratio and regions, and our 
current working hypothesis states that these epigenetic 
changes, as minuscule as they may be, have significant 
outcomes for the cell and the organism.   
 
Case in point, we propose, infection of immune cells that 
express the cluster of differentiation (CD) 4 by the human 
immunodeficiency virus (HIV)-1, and integration of viral 
genomic structures into the DNA of its host most likely alters 
the structure-function relationship of chromatin.  One 
putative outcome is a significant degree of nucleotide 
divergence in the untranslated regions (UTRs) of mature 
mRNA intronic as well as intergenic DNA sequences. The 
rationale and salient supporting literature are discussed in Bioinformation by Biomedical Informatics Publishing Group                                    open access 
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Part I and II of this hypothesis. HIV-1 infects CD4+ cells, 
and chemokine receptors serve as co-receptors for infection 
by binding to certain HIV-1 envelope proteins (e.g., CXCR4 
favors X4 HIV-1 strain T cell tropism, CCR5 favors R5 
strain tropism). A subpopulation of CD4+ T lymphocytes 
involved in regulatory processes of cellular immune 
responses, regulatory T cells (Tregs), express CCR5, are 
CXCR4/CXCL12+, and are highly susceptible to HIV-1 
infection. Tregs harbors viral replication [2-4].  
 
Depletion of Tregs enhances the proliferation of the 
remaining CD4+ population Sub-sets of Tregs vary in their 
expression of the homing receptor, CD62L, and their ability 
to migrate to peripheral lymph nodes [5]. These subsets are 
activated CD4+CD25+ cells that also express FoxP3, a 
transcriptional repressor that targets composite NF-AT/AP-1 
sites in cytokine gene promoters. The expression of FoxP3 is 
stabilized by epigenetic modifications to allow the 
establishment of Tregs into a long-term cell lineage [6]. 
FoxP3-transduced T-cells are markedly more susceptible to 
HIV-1 infection, and HIV-positive individuals with a low 
percentage of CD4+ and higher levels of activated T-cells 
have greatly reduced levels of FoxP3+CD4+CD25+ T-cells 
[3, 7].  
 
Methodology: 
As methodological research approaches are devised to test 
the role of epigenetic modulation in the immunopathology of 
HIV/AIDS, it must be considered that Neuropilin-1 (Nrp1) is 
a plasma trans-membrane receptor (120 kDa) involved in 
axon guidance, angiogenesis, and the activation of T cells. 
CD4+CD25+ Tregs are constitutively Nrp1+. Nrp1 binds to 
the class 3 semaphorin subfamily and the heparin-binding 
forms of vascular endothelial growth factor and placenta 
growth factor. By mediating contact between dendritic and T 
cells via homotypic interactions, Nrp-1 is critical to the 
initiation of the primary immune response, but it is down-
regulated in naïve CD4+CD25- T cells following TcR 
stimulation. Molecular cartography demonstrates that Nrp-1 
signaling is mediated through its C-terminal domain and 
downstream molecules, including phosphoinositide 3-kinase. 
Specific and effective silencing of the regulators of G-protein 
signaling(RGS)- Gα-interacting protein (GAIP)-interacting 
protein C terminus (GIPC) domain in vascular endothelium 
results in inhibition of Nrp1-mediated migration [3, 8].   
 
Epigenetic studies show that, in the case of human papilloma 
virus (HPV), HPV-18 E6 renders cells less sensitive to the 
cytostatic effect of tumor necrosis factor (TGF)-β by 
lowering the intracellular amount of TIP-2/GIPC [9]. 
Whether or not similar observations might apply to HIV-1 
infection remains to be elucidated.  
 
Discussion: 
Taken together, these lines of evidence indicate that Tregs are 
premier candidates for epigenetic studies of non-coding DNA 
in HIV/AIDS, and NeuroAIDS. We hypothesize that, by 
inserting itself in the host genome, HIV alters the chromatin 
in such a manner as to unveil otherwise non-coding DNA, 
thus favoring, for instance, the expression of CD62L. The 
suppressive function of the CD62L+ subset of Tregs is by far 
more potent on a per cell basis, than its CD62L- Tregs 
cohort, and it avidly proliferates, expands readily, and is very 
responsive to chemokine-driven migration [10]. CD62L+ 
Tregs are most likely to migrate across the blood-brain 
barrier  [11] and to contribute profoundly to the in situ 
immunopathology of NeuroAIDS. 
 
That Treg are susceptible to HIV-1 infection is also pertinent 
to clinical decision-making for treatment intervention, and 
opens the way to an emerging field that may be termed 
translational evidence-based epigenetic medicine. Patients 
with HIV/AIDS with a low percentage of CD4+, typically 
have greatly reduced numbers of FoxP3+CD4+CD25+ T 
cells. CD25+ T cells expand significantly in peripheral blood 
of HIV-seropositive patients receiving highly active 
antiretroviral therapy (HAART), and exhibit phenotypic (e.g., 
CD25, CXCR4), molecular (e.g., FoxP3), and functional 
characteristics (e.g., impaired proliferative and IL-2 
production responses) of Tregs [7]. This response appears 
specific since recent local immunity studies have established 
that the frequency and the absolute number of mucosal, but 
not of peripheral blood FoxP3+ Tregs significantly increase 
in untreated HIV-seropositive patients, but normalize 
following HAART treatment [12].   
 
Cytokines, through signal transduction pathways, elicit 
homeostatic mechanisms that regulate the survival and 
proliferation of immune cells. Dendritic cells and other 
antigen presenting cells produce regulatory amounts of 
interleukin (IL)-10, IL-12, IL-15 and IL-4, which lead T cells 
either to a TH1 or a TH2 pattern of cytokines [3, 13]. The 
regulatory contribution of non-coding DNA to this process is 
emerging  [13]. Recent data have established, during both 
TH1 and TH2 differentiation of human neonatal CD4+ T 
cells, characteristic alterations in chromatin architecture at 
specific loci. Specifically, cis-regulatory elements that 
pointed to the acquisition of permissive chromatin structure 
at the proximal promoter were seen in TH2 cells, rather than 
the formation of locus-wide repressive chromatin in TH1 
cells [14]. 
 
Infection of CD4+ immune cells by HIV-1 alters TH1/TH2 
modulation, and the TH1/TH2 ratio [3], which, under normal 
conditions, is kept under control in part by Tregs, and 
counter-modulated by cytokines, including interferon (IFN)-
γ, IL-10 and IL-4 [3]. That Tregs are putatively involved in 
suppressing TH1 cytokine responses to ensure polarization of 
the TH2 pattern of cytokines during an immune response is 
questionable, in light of recent data. The Tregs population is 
complex in nature and function, as indicated above. It is 
composed of several overlapping sub-populations with 
specialized regulatory functions. The defining principle of 
Tregs is the lack of effector functions due to a partial or Bioinformation by Biomedical Informatics Publishing Group                                    open access 
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incomplete differentiation to either TH1 or TH2. The role of 
non-coding regions in actualizing this fine functional 
modulation of Tregs must now be explored. 
 
Additional patterns of cytokines are involved in the 
regulatory arm of the cellular immunopathology of 
HIV/AIDS, including the IL-10 family (i.e., IL-20 and related 
cytokines) [15], and the inflammatory arm of the response. It 
is now clear that certain growth factors (e.g., 
granulocyte/macrophage-colony stimulating factor (GM-
CSF) modulate the increase the production of bone marrow-
derived antigen-presenting dendritic cells, and the production 
of IL-23 by these cells. IL-23, a member of the IL-12 
cytokine family, shares p40, and binds to the IL12β1/IL-23R 
receptor complex. It plays a critical role in end-stage 
inflammation via signaling of the Janus tyrosine kinases (Jak) 
and signal transducers and activators of transcription (Stat) 
(JAK/STAT) pathway. This pattern of cytokine is an 
“inflammatory helper T cell differentiation” (i.e., 
inflammatory Thelper cells, THi) [3, 16].  
 
Administration of IL-11 down-regulates IL-12. IL-23 
augments production of IL-17 by T cells, which becomes the 
significant cytokine in the involvement of T cells in 
mediating and regulating the inflammatory process. IL-17 
down-regulates neutrophils, and in vitro it synergizes the 
effects of TNFα for GM-CSF induction, for increased 
intercellular adhesion molecule (ICAM)-1 (CD54) expression 
by CD34+ progenitors, for increased neutrophil maturation, 
and for increased pro-inflammatory IL-6 and prostaglandin 
(PG)E2 and G-CSF growth factor production by 
keratinocytes and endothelial cells. IL-17 thus favors 
increased secretion of the migration-inducing cytokine, IL-8. 
Whether or not these processes are mediated through GIPC is 
speculative at present, and remains to be tested. In human 
U937 cells, and probably in all lymphoid and myeloid cells, 
the JAK/STAT signaling pathway is responsible for 
transducing signals from the IL-17 receptor. Human vascular 
embryonic cells (HUVEC) express a homologue of IL-17R, 
as do ductal epithelial cells of human salivary glands, 
suggesting a significant role for IL-17 in mucosal immunity. 
In fact, in inflamed gingival tissue, IL-17 is the predominant 
cytokine in tissue proximal to 4-5 mm diseased periodontal 
pockets. IL-17 plays a critical role in immunity and mucosal 
inflammation, by modulating the effects of GM-CSF and 
other growth factors [3, 16]. 
 
Non-coding DNA plays an important role in regulating 
cytokine patterns. It is clear that genomic manipulation of T 
cells in vitro, such as the introduction of FoxP3 into 
conventional mouse T cells, has the critical outcome of 
converting these cells to the Tregs phenotype. Patients with 
mutations at the FoxP3 site show significant impairments in 
Tregs function [17]. 
  
 
Figure 1: Representation of our hypothetical model of epigenetic modification of Tregs following infection by HIV-1. 
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It is also established that CD4+ cells can manifest extensive 
changes in chromatin structure and architecture. The 
chromatin in the TH1 and TH2 lineages undergo locus-
specific remodeling during cytokine pattern polarization [14, 
18, 19]. THi produce IL-17 and IL-17F, two highly 
homologous cytokines that have genes located in the same 
chromosomal region, undergo a series of chromatin 
remodeling events during their lineage polarization similar to 
that which characterize TH1 and TH2 cells, such that 
epigenetic modifications such as histone H3 acetylation and 
Lys-4 tri-methylation are specifically associated with IL-17 
and IL-17F gene promoters in the THi lineage. Early during 
the T cell activation state, histone acetylation on these 
promoters is synergized by TGFβ and IL-6, suggesting a role 
for these cytokines is permitting chromatin accessibility for 
transcription factors. Multiple noncoding sequences exist 
within the IL-17-IL-17F locus that appear to be conserved 
across species, and that also are associated with hyper-
acetylated histone 3 in a lineage-specific manner, confirming 
the stringency of these regulatory regions [20].  
 
In brief, it is conceivable that, mechanistically, these and 
other epigenetic transformations of the chromatin structure, 
putatively following the insertion of infecting HIV-1, lead to 
an important imbalance in the proportion of circulating and 
functional Tregs, and to cytokine imbalance (Figure 1). This 
hypothesis is timely in view of the observations that in 
latently infected resting CD4+ lymphocytes, HIV-1 
transcription appears repressed by de-acetylation events 
mediated by histone de-acetylases. Reactivation of HIV-1 
from latency engages a displacement of these histone de-
acetylases by means of histone acetyl-transferases in an NF-
κB-mediated mechanism, and leads to viral transcriptional 
activator Tat and multiple acetylation events. Following this 
chromatin remodeling in the domain of the viral promoter 
region, transcription is initiated and leads to the formation of 
the trans-acting response element (TAR) element. The 
complex of Tat with the human positive transcription 
elongation factor (p-TEF)β then binds the loop structures of 
TAR RNA. p-TEFβ is composed of Cdk9 and cyclin T1, and 
acts a general transcription elongation factor that 
phosphorylates the C-terminal domain of RNA polymerase 
II. Thus, CDK9 is positioned by this chromatin remodeling to 
phosphorylate the cellular RNA polymerase II. The Tat-
TAR-dependent phosphorylation of RNA polymerase II 
contributes significantly to transcriptional elongation and 
post-transcriptional events [21]. 
 
Prior to coining the term, “single nucleotide polymorphism” 
(SNP), variations in coding and non-coding sequences of the 
major histocompatibility complex (MHC) were used to 
delineate ancestral haplotypes [22]. Ongoing systematic 
analyses aimed to verify SNPs across MHC are critical for 
vaccine development. That short antigen oligopeptides bind 
specifically to different human leukocyte antigen (HLA) 
alleles representing varying ethnic populations, and are 
combinatorial in selection, helps to differentiate between self 
and non-self [3]. Advances in Bioinformatics yield 
algorithms for HLA specific short antigen peptide binding [4, 
23], and functional overlap across alleles at multiple levels as 
HLA super-types is complex given the over 2000 known 
HLA alleles and the extensive diversity across peptide 
constructs, and under continuing research [24]. For example, 
HLA-A to HLA-E genes, located in chromosome region 
6p21.3, are associated with a large variety of diseases (e.g., 
vascular dementia, epilepsy, schizophrenia, diabetes, viral 
pathogenesis, cancer, graft vs. host disease). Additional 
conditions are distributed elsewhere on the same 
chromosome (cf., Table 1 under supplementary material) 
[25]. In fact there seems to be a concentration of 
neuropsychiatric diseases located on this chromosome, whose 
collection of genes may interact in the NeuroAIDS process.  
 
Conclusion:  
Taken together, the literature discussed above emphasizes the 
critical role of Tregs in the immunopathology of HIV/AIDS, 
and opens new potential modes of intervention based on 
manipulations of non-coding portions of the genome. It 
suggests the timely development of translational evidence-
based epigenetic medicine [26], whose implications are 
discussed in the following paper from the specific viewpoint 
of the viropathology of AIDS and NeuroAIDS, and 
translational implications. 
 
It is therefore important to note, in conclusion, that 
translational evidence-based decision-making in epigenetic 
medicine will in fact pertain beyond HIV/AIDS, including 
cancer and related pathologies. Case in point, the 100-1000X 
increased prevalence of carcinoma at the site of Oral Lichen 
Planus  [27], an oral condition whose neuro-
immunopathology we have examined extensively [28]. 
Cancer development at the sites of the lesions is particularly 
aggressive in proximity to recently placed titanium dental 
implant [27]. Whereas titanium is considered inert in most 
patients, it can produce significant epigenetic modulation in 
patients at risk, and it was proposed that such altered gene 
expression leads to the development of neoplasia [29]. 
 
The concepts articulated here in the domain of TH1/Th2 
cytokine shift [30] and related immunopathological 
consequences of HIV/AIDS are coherent with the emergent 
principle of recursive genome function [31] further examined 
in the context of the viropathology of neuroAIDS [32].  
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Supplementary material 
 
Condition, susceptibility to  Gene symbol  OMIM #  location 
Nystagmus-2, autosomal dominant  NYS2, NYSA  164100 6p12 
Epilepsy, juvenile myoclonic   EJM3  608816 6p21 
Migraine with or without aura MGR3  607498 6p21.1-p12.2 
Ankylosing spondylitis  AS  106300  6p21.3 
Creutzfeldt-Jakob disease, variant, resistance   HLA-DQB1  604305 6p21.3 
Deafness, autosomal dominant COL11A2,STL3,  DFNA13  120290 6p21.3 
Dementia, vascular TNF,  TNFA  191160 6p21.3 
Malaria, cerebral TNF,  TNFA  191160 6p21.3 
Migraine without aura TNF,  TNFA  191160 6p21.3 
Multiple sclerosis HLA-DQB1  604305 6p21.3 
Multiple sclerosis HLA-DR1B  142857 6p21.3 
Myasthenia gravis with thymus hyperplasia  MYAS1  607085 6p21.3 
Autism GLO1  138750 6p21.3-p21.2 
Dyslexia  KIAA0319, DYX2, DYLX2, DLX2  609269 6p22.2 
Epilepsy, myoclonic, Lafora type  NHLRC1,EPM2A, EPM2B  608072 6p22.3 
Schizophrenia DTNBP1,  HPS7  607145 6p22.3 
Maple syrup urine disease-Ib  BCKDHB, E1B  248611 6p22-p21 
Spinocerebellar ataxia-1  ATXN1, ATX1, SCA1  601556 6p23 
Spinocerebellar ataxia with blindness and deafness   SCABD  271250 6p23-p21 
Attention deficit-hyperactivity disorder  ADHD3  608905 6q12 
Deafness, autosomal dominant & recessive  MYO6, DFNA22, DFNB37  600970 6q13 
Multiple sclerosis CD24  600074 6q21 
Muscular dystrophy, congenital merosin-deficient LAMA2,  LAMM  156225 6q22-q23 
Muscular dystrophy, congenital, due to partial 
LAMA2 deficiency 
LAMA2, LAMM  156225 6q22-q23 
Febrile convulsions, familial  38753  609255 6q22-q24 
Refsum disease  PEX7, RCDP1  601757 6q22-q24 
Deafness, autosomal dominant  EYA4,DFNA10, CMD1J  603550 6q23 
Schizophrenia TAAR6,TRAR4,  SCZD5  608923 6q23.2 
Zellweger synd., complementation group  PEX3  603164 6q23-q24 
Epilepsy, myoclonic, Lafora type  EPM2A, MELF, EPM2  607566 6q24 
Migraine ESR1,  ESR  133430 6q25.1 
Parkinson disease, juvenile-2  PRKN, PARK2, PDJ  602544 6q25.2-q27 
Deafness, autosomal recessive  DFNB38  608219 6q26-q27 
Huntington disease-like-4  TBP, SCA17  600075 6q27 
Parkinson disease   TBP, SCA17  600075 6q27 
Table 1: Select genes and Diseases associated with chromosome 6. (From: MHC sequencing consortium, The complete sequence 
and gene map of a human major histocompatibility complex, Nature, 401, 921-923, 1999; OMIM: 
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=OMIM; OMIM Morbid map: 
http://www.ncbi.nlm.nih.gov/Omim/getmorbid.cgi) 
 
 
 